Annabel Samimy

Anupam Rama

Douglas Tsao

Jonathan Miller

Lachlan Hanbury-Brown

Yigal Nochomovitz

Biren Amin

Graig Suvannavejh

Lisa Walter

Ryan Deschner

Colleen Kusy

Judah Frommer

Divya Rao

Joe Thomas

Katherine Wang

Shrunatra Mishra

Simone Nasroodin

Timur Ivannikov

Derek Archila

Eliana Merle

Salveen Richter

Tazeen Ahmad

Jasmine

Philip Nadeau

Akash Tewari

Colin Kosse

Greg Harrison

Gregory Harrison

Joseph Stringer

Laura Chico

Nicholas Econom

Phil Nadeau

Steven Seedhouse

- Apellis Pharmaceuticals reported a **strong balance sheet** following a recent royalty monetization deal with Sobi, which added **$275 million**.  **[1492422_tx_379961_0]** 
- EMPAVELI recently received approval for C3G and IC-MPGN, expanding its market by approximately **5,000 patients** and showing strong early launch indicators, with the company anticipating it can become a **blockbuster product** across its indications.  **[1492422_tx_379961_0]** **[1492422_tx_379961_1]** **[1492422_tx_379961_4]** 
- SYFOVRE, the **market leader** in geographic atrophy, has stabilized its performance and is projected for **low to mid-single-digit growth**.  **[1492422_tx_379961_5]** **[1492422_tx_379961_6]** 
- The company is advancing its pipeline, including APL-3007 to enhance SYFOVRE and exploring further indications for EMPAVELI.  **[1492422_tx_379961_0]** **[1492422_tx_379961_9]**

Apellis Pharmaceuticals Discusses Strong Balance Sheet, Product Growth, and Pipeline

Apellis Pharmaceuticals (APLS)